PharVision Advisers’s Immersion IMMR Stock Holding History

PharVision Advisers’s Portfolio IMMR Stock Details IMMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-42,137	Closed	-$309K	–	838
2025 Q3	$309K	Buy	42,137 +16,599	+65%	+$120K	0.17%	210
2025 Q2	$201K	Sell	25,538 -940	-4%	-$6.99K	0.29%	205
2025 Q1	$201K	Buy	26,478 +3,349	+14%	+$27.5K	0.28%	200
2024 Q4	$202K	Buy	+23,129	New	+$202K	0.17%	304

Other funds holding IMMR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CDC Financial Chicago, Illinois $157M AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAM

Nissay Asset Management Tokyo, Japan $18.9B AUM 27.21% 1-Year Est. Return

Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

PharVision Advisers's IMMR Position: Q4 2025 in Review

PharVision Advisers sold out of Immersion (IMMR) in Q4 2025, closing a stake of 42,137 shares — an estimated $309K sold.

PharVision Advisers first reported a position in IMMR in Q4 2024 and held it in 4 quarters. The position peaked at $309K in Q3 2025. 116 funds tracked by Wall St. Rank hold IMMR as of Q4 2025.

PharVision Advisers reported no remaining Immersion position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 42,137 Immersion shares in Q4 2025, an estimated $309K.
PharVision Advisers first reported a position in Immersion in Q4 2024 and held it in 4 quarters.
PharVision Advisers's Immersion position peaked at $309K in Q3 2025.
116 funds tracked by Wall St. Rank held Immersion as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.